We strive to save lives by enabling timely intervention
and improving patient outcomes worldwide.

ExoSphere is pioneering a new approach that combines advanced microfluidics
with highly sensitive biomarker detection technology.

    ExoSphere logo

Unique Techology

Our platform is designed to capture and detect disease-specific molecules at extremely low concentrations, enabling earlier and more reliable diagnosis than current standard methods.

Speed, Affordability, Scalability

Unlike conventional technologies, our solution emphasizes speed, affordability, and scalability without compromising precision. This makes it suitable not only for cutting-edge research but also for widespread clinical use.

Applications

Our platform has broad applications across oncology diagnostics and beyond, including areas such as cardiovascular and infectious diseases. While the technology is versatile, our current focus is on breast, colorectal, and lung cancer—where early,(and) precise detection can have the greatest impact.

Team

Negar Shahmoradi

Negar Shahmoradi

CEO

Business Development and Strategy

Patricia Graça

Patricia Graça

CSO

Scientific Validation

Markus Rinecker

MD, MBA Markus Rinecker

CMO/CFO

Medical Guidelines and Workflow Integration

Moritz Leuthner

Moritz Leuthner

Technical Advisor

Technical Development and Validation

Sebastian Schwaminger

Assoc. Prof. Sebastian Schwaminger

Scientific Advisor

Biochemistry and IP

Oliver Hayden

Prof. Dr. Oliver Hayden

Scientific Advisor

Microfluidics

Contact us: contact@exosphere.bio